Education
About Us
Working with TipRanks
Follow Us
RenovoRx (RNXT)
NASDAQ:RNXT
RNXT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.77 - $1.69
Previous CloseN/A
Volume39.72K
Average Volume (3M)116.12K
Market Cap
$37.70M
Enterprise Value$16.87M
Total Cash (Recent Filing)-$2.10M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.54
Next Earnings
May 19, 2025EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding35,565,250
10 Day Avg. Volume70,051
30 Day Avg. Volume116,119
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.45
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.43
Forecast
1Y Price Target
$9.00Price Target Upside749.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsPositive interim analysis results suggest a 6-month potential improvement in median overall survival with RenovoGem, with no safety concerns observed.
Market PotentialPancreatic cancer is one of the deadliest cancers in the U.S., presenting a large market potential for treatments like RenovoGem.
ValuationThe current valuation is considered attractive, with a raised 12-month price target to $9.00, representing significant upside from the current share price.
Bears Say
Clinical Trials RiskThe RenovoTAMP platform still has long development roads left and high risks of clinical trials failures.
Financial PerformanceRenovoRx reported 3Q24 results with a net loss of ($2.4M) and ended the period with $9.5M in cash on the balance sheet.
---
Ownership Overview
0.33%
Insiders
1.16% Mutual Funds
0.87% Other Institutional Investors
94.28% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
RNXT FAQ
What was RenovoRx’s price range in the past 12 months?
RenovoRx lowest stock price was $0.77 and its highest was $1.69 in the past 12 months.
What is RenovoRx’s market cap?
RenovoRx’s market cap is $37.70M.
When is RenovoRx’s upcoming earnings report date?
RenovoRx’s upcoming earnings report date is May 19, 2025 which is in 53 days.
How were RenovoRx’s earnings last quarter?
RenovoRx released its earnings results on Nov 14, 2024. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.117 by $0.017.
Is RenovoRx overvalued?
According to Wall Street analysts RenovoRx’s price is currently Undervalued.
Does RenovoRx pay dividends?
RenovoRx does not currently pay dividends.
What is RenovoRx’s EPS estimate?
RenovoRx’s EPS estimate is -0.12.
How many shares outstanding does RenovoRx have?
RenovoRx has 35,565,250 shares outstanding.
What happened to RenovoRx’s price movement after its last earnings report?
RenovoRx reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.117. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of RenovoRx?
Currently, no hedge funds are holding shares in RNXT
---
RenovoRx Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (749.06% Upside)
$9.00 (749.06% Upside)
Blogger Sentiment
Bullish
RNXT Sentiment 100%
Sector Average 69%
Sector Average 69%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.87%
12-Months-Change
Fundamentals
Return on Equity
-258.95%
Trailing 12-Months
Asset Growth
185.05%
Trailing 12-Months
Company Description
RenovoRx
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
---
RNXT Stock 12 Month Forecast
Average Price Target
$9.00
▲(749.06% Upside)
Technical Analysis
Best Analysts Covering RNXT
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-35.63%
reiterated a buy rating 12 months ago
Copying Scott Henry's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -35.63% per trade.
---